Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Palobiofarma (Details)

v3.24.3
Royalty and Commercial Payment Purchase Agreements - Palobiofarma (Details)
$ in Thousands
9 Months Ended
Sep. 26, 2019
USD ($)
item
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Agreements        
Payments of consideration under RPAs, AAAs and CPPAs   $ 37,000 $ 14,650  
Long-term royalty and commercial payment receivables   54,207   $ 57,952
Short-term royalty and commercial payment receivables   12,682   14,215
Palobiofarma | Royalty Purchase Agreement        
Agreements        
Number of drug candidates | item 6      
Payments of consideration under RPAs, AAAs and CPPAs $ 10,000      
Long-term royalty and commercial payment receivables $ 10,000      
Allowance for credit losses   $ 0   $ 0